Following internalisation viruses have to escape the endocytic pathway and deliver their 20 genomes to initiate replication. Members of the Polyomaviridae transit through the 21 endolysosomal network and through the endoplasmic reticulum (ER), from which heavily 22 degraded capsids escape into the cytoplasm prior to nuclear entry. Acidification of 23 endosomes and ER entry are essential in the lifecycle of polyomaviruses, however many 24 mechanistic requirements are yet to be elucidated. Alteration of endocytic pH relies upon the 25 activity of ion channels. Using two polyomaviruses with differing capsid architecture, namely 26 Simian virus 40 (SV40) and Merkel cell polyomavirus (MCPyV), we firstly describe methods 27 to rapidly quantify infection using an IncuCyte ZOOM instrument, prior to investigating the 28 role of K + and Ca 2+ channels during early stages of infection. Broad spectrum inhibitors 29 identified that MCPyV, but not SV40, is sensitive to K + channel modulation. In contrast, both 30 viruses are restricted by the broad spectrum Ca 2+ channel inhibitor verapamil, however 31 specific targeting of transient or long lasting Ca 2+ channel subfamilies had no detrimental 32 effect. Further investigation revealed that tetrandrine blockage of two-pore channels (TPCs),
could be repurposed to restrict persistent polyomavirus infection and may ultimately prevent 48 polyomavirus-associated disease.
INTRODUCTION
114 timescales (Fig. 1E-F) (25) . Using these systems, SV40 infections and MCPyV 115 transductions could be performed in a 96-or 24-well plate format, respectively, providing a 116 platform for high-throughput antiviral compound screening.
117
It is well established that PyVs traffic through the endo/lysosomal system where acidification 118 initiates proteolytic rearrangements to promote virus disassembly. To validate our Incucyte-119 based system, we assessed virus infection in the presence of ammonium chloride (NH 4 Cl), a 120 known inhibitor of endosomal acidification. Consistent with previous studies, NH 4 Cl 121 treatment reduced MCPyV and SV40 infection by 87% and 54% respectively, further 122 validating the system ( Fig. 2A & C) . However, despite knowledge that acidification is 123 important, the endosomal progression of PyVs prior to ER translocation remain unclear. To 124 determine whether the viruses enter late endosomes and/or lysosomes, cells were treated 125 with 2-[(4-Bromophenyl) methylene]-N-(2, 6-dimethylphenyl)-hydrazinecarboxamide (EGA) 126 to inhibit lysosomal clustering prior to virus infection. Treatment with EGA led to a 75% and therefore explored whether regulators of two of the major endosomal ion channel families, 134 namely K + or Ca 2+ channels, were important for PyV entry. Treatment of cells with the broad 135 spectrum K + channel inhibitor tetraethylammonium (TEA) and broad-spectrum Ca 2+ channel 136 inhibitor verapamil inhibited MCPyV infection by 62% and 57%, respectively, suggesting that 137 both channel families were important during MCPyV entry (Fig. 3A-B) . In contrast, TEA had 138 little to no-effect on SV40 infection (Fig. 3C) , whereas Verapamil treatment caused a 57% 139 loss of SV40 infection (Fig. 3D) . This suggested a requirement for Ca 2+ channels is 140 conserved across both viruses.
141
Identification of the K + channels required during MCPyV entry 142 K + channels are the most diverse class of membrane proteins expressed with the cell (57).
143
There are four subfamilies that are ubiquitously expressed across nearly all kingdoms of life:
144
(i) voltage-gated K + channels (K V ) (6 transmembrane domains (TMDs)), (ii) inwardly 145 rectifying K + channels (K IR ) (2 TMDs), (iii) tandem pore domain K + channels (K 2P ) (4 TMDs) 146
and (iv) Ca 2+ activated K + channels (K Ca ) (6 TMDs) (58). To identify which K + channel 147 subfamilies are required during MCPyV entry, we investigated the effects of KCl (to destroy 148 K + gradients and thus K + channel function) and 4-aminopyridine (4AP, a K V channel blocker) 149 on MCPyV and SV40 infection. Both KCl and 4AP inhibited MCPyV but neither affected 150 SV40 ( Fig. 4A-B) . Furthermore, the anti-malarial drug quinine that promiscuously blocks a 151 variety of K + channels through an unknown mechanism had no effect on either MCPyV or 152 SV40. These data highlighted differences in MCPyV and SV40 entry processes and 153 suggested that MCPyV can be blocked by inhibitors of 4AP sensitive, quinidine insensitive 154 Kv channels.
155

Blockers of L-type Ca 2+ channels restrict MCPyV entry
156
Given that K + channel inhibition did not display a conserved effect upon MCPyV and SV40 157 entry, the effect of verapamil was further investigated. Verapamil inhibits both Transient (T-158 type, low-voltage activated) and long lasting (L-type, high-voltage activated) Ca 2+ channel 159 family members. Therefore, a range of more specific Ca 2+ blocking drugs were assessed for 160 their effects on SV40 and MCPyV. Treatment with the T-type inhibitor flunarizine led to an 161 83% inhibition of MCPyV infection, whilst nitrendipine (an L-type Ca 2+ channel blocker) had 162 no significant effect ( Fig. 5A-B) . Both flunarizine and nitrendipine did not affect SV40 entry 163 suggesting that the requirement for T-type Ca 2+ channels is limited to MCPyV (Fig. 5C-D) .
164
Blockers of two pore Ca 2+ channels inhibit MCPyV and SV40
165
It has previously been shown that verapamil, alongside a panel of classical L-type inhibitors 166 could inhibit the entry of EBOV (41). Further investigation however identified that EBOV did not not require L-type Ca 2+ channel activity, with blockage of NAADP-dependent TPCs that 168 regulate endosomal Ca 2+ signalling, sufficient in preventing endolysosomal fusion of virus-169 containing vesicles with the ER. Given that PyVs traffic through the ER and verapamil 170 showed an effect that was independent of the assessed Ca 2+ channel inhibitors, the 171 importance of TPCs during MCPyV and SV40 entry was investigated. Gabapentin, an L-type 172 Ca 2+ channel inhibitor had no effect on MCPyV or SV40, which was comparable with 173 nitrendipine treatment ( Fig. 6A & C) . However, treatment with the TPC inhibitor tetrandrine 
179
TPC inhibition prevents SV40 ER disassembly 180
Although proteolytic rearrangements are initiated in acidifying endosomes, SV40 capsid 181 disassembly sufficient for minor capsid protein exposure does not occur until the virion is 182 processed in the ER (~6-8 hpi), with detection in the cytoplasm at 10 hpi (30). To confirm a 183 role of TPCs during SV40 entry, virus supernatants were added to cells at 4°C to 184 synchronise infection, prior to the addition of pre-warmed medium containing vehicle or 185 inhibitor for 10 h. Cells were then fixed and immunostained for VP2/3 to detect disassembled 186 virions in the ER and cytoplasm. We observed distinct puncta in cells treated with vehicle or 187 gabapentin ( Fig. 7) . In contrast, cells treated with tetrandrine displayed no detectable puncta 188 confirming that the capsid was unable to disassemble and expose the minor capsid NLSs 189 required for transit to the nucleus. These results highlight an essential requirement for 190 NAADP-stimulated Ca 2+ channel activity during SV40 infection.
DISCUSSION
192
To date, studies regarding early events in the lifecycle of PyVs are limited. All studied PyVs 193 traffic through the endo/lysosomal network during virus entry, which we confirmed for both 
200
There is a long-standing acceptance that acidification of maturing endosomes and 201 lysosomes is due to the translocation of H + , which whilst true, only reflects one aspect of the 202 highly dynamic ionic flux that regulates compartmental pH (59). Given that ion channels 203 regulate a wide variety of cellular functions, there is an array of well characterised 204 pharmaceutically available drugs that can be used to treat many diseases. The ability to 205 identify and repurpose drugs is therefore a viable and cost effective means of restricting
206
PyV-associated diseases.
207
The entry of Bunyaviruses and Filoviruses have been shown to require K + and Ca 2+ 208 channels, respectively (38, 42) . Therefore TEA and verapamil were applied during 209 attachment and entry of MCPyV and SV40. The results indicated that MCPyV required both 210 K + and Ca 2+ channel activity, whilst SV40 trafficking was solely sensitive to Ca 2+ channel 211 blockage (Fig. 3) . The use of a wider panel of K + channel inhibitors suggested that MCPyV 212 required the activity of K V channels (Fig. 4A) . Insensitivity to K + channel inhibitors during 213 SV40 infection ( Fig. 4B ) highlighted mechanistic differences between MCPyV and SV40.
214
Importantly, neither blocker inhibited SV40 so their effects cannot be mediated through 215 modulation of endosomal pH. However, further screening with other human PyVs such as 216 JCPyV and BKPyV may identify conserved requirements that could be targeted in the 217 treatment of PyV-associated disease in humans.
218
Due to conserved sensitivity of MCPyV and SV40 upon challenge with verapamil, the role of 219 Ca 2+ channels was further explored. Treatment with flunarizine and nitrendipine, T-and L-220 type Ca 2+ channel inhibitors, respectively, produced surprising results ( Fig. 5A-D) . Whilst
221
MCPyV was sensitive to T-type Ca 2+ channel inhibition there was no observed inhibition of 222 SV40 with either drug, again highlighting differences between MCPyV and SV40 during 223 entry. The lack of phenotypic change for SV40 was however comparable to data relating to 224 Ebola virus (EBOV), where verapamil was shown to prevent docking of virion-containing 225 endosomes with the ER through inhibition of NAADP-sensitive Ca 2+ channels (41). EBOV inhibition was further characterised to be via NAADP-sensitive TPC1/2 activity, therefore we 227 similarly investigated whether TPC inhibition could restrict MCPyV and SV40. Treatment 228 with the L-type Ca 2+ channel gabapentin had no effect upon entry of MCPyV or SV40 ( Fig.   229 6A&C). However, treatment with the NAADP-sensitive Ca 2+ channel inhibitor tetrandrine 230 showed a concentration-dependent effect upon both viruses, with ablation of entry for 231 MCPyV and SV40 at 5 µM and 10 µM, respectively (Fig. 6B&D) . As tetrandrine-mediated 232 inhibition of EBOV entry was due to the prevention of ER docking, a viral uncoating assay for 233 SV40 was performed as further validation (Fig. 7) . Consistent with previous results, following 234 treatment with 10 µM tetrandrine VP2/3 was undetectable, confirming that virions either did 235 not enter the ER or were unable to disassemble to reveal VP2/3 (summarised in Fig. 8 ).
236
Identification that PyVs share a conserved requirement with EBOV suggests that NAADP-237 sensitive TPC inhibition represents a therapeutic target for viruses and pathogens that traffic 238 through the ER during entry stages. Although tetrandrine is not widely available and there 239 are currently limited studies into the efficacy of treatment in vivo, the identification of 240 endosomal-ER fusion as a requirement for a variety of pathogens provides a common target 241 that could potentially be exploited (60, 61).
242
In conclusion, we provide the first evidence that repurposing of clinically available drugs that 243 modulate ion channel activity are a viable method of restricting PyV infection. This study 244 identifies that MCPyV is more sensitive to channel inhibition than SV40, with K V and T-type 245 Ca 2+ channel inhibition restricting entry which may be applicable to other humans PyVs.
246
Additionally we have demonstrated that the NAADP-sensitive TPC inhibitor tetrandrine is a 247 potent inhibitor of both MCPyV and SV40. Ca 2+ channel modulation is therefore a potential 248 mechanism through which human PyV diseases associated with persistent infection could 249 be modulated. Coupled with previous studies, this requirement reveals a conserved target to 250 restrict a wider range of pathogens that transit through the ER. 
273
To determine virus stocks 5x10 3 Vero cells were seeded into wells of a 96-well plate 18 274 hours prior to infection. Virus stocks were diluted 5-fold prior to a 2-fold dilution series using 
SV40 infection assay
285
Vero cells (5x10 3 /well) were seeded into 96-well plate 18 hours prior to experimentation. If 286 applicable, cells were pre-treated with chemical inhibitors for 1 hour. SV40 virions were 287 diluted in complete DMEM (containing chemical inhibitors if applicable) to achieve an MOI of 288 1 relative to initial seeding and incubated on cells for 2 hours with gentle rocking every 30 289 minutes before aspiration and addition of fresh complete DMEM. Cells were fixed 24 hpi, 290 immunostained, imaged and analysed using an Incucyte ZOOM System as previously 291 described. Inhibitor effects were calculated through comparison to untreated controls.
292
Percentage confluence was calculated by Incucyte ZOOM analysis to ensure cell 293 proliferation in drug-treated wells, with <80% confluence omitted.
294
MCPyV PsV production 295 Production of MCPyV PsVs has been previously described (14, 21, 62, 63) . Briefly, 293TT 296 cells were transfected with pwM2m, ph2m and pEGFP-C1 and harvested by trypsinisation 
571
Vero cells were incubated with drug as described for 1 hour before addition of SV40 virions 572 at an MOI of 1 for 2 hours with occasional agitation. Fresh drug-containing medium was then 573 added for an incubation of 24 hours before fixation and permeabilisation. SV40 T-antigens 
579
(A+B) 293TT cells were incubated with drug as described for 1 hour before addition of 10 ng 580 VP1-equivalent MCPyV GFP PsVs for 2 hours with occasional agitation. PsV containing 581 medium was removed and replaced with fresh drug-containing medium, with Incucyte 582 detection 72 hours post transduction to determine the number of GFP-positive cells. (C+D)
583
Vero cells were incubated with drug as described for 1 hour before addition of SV40 virions 584 at an MOI of 1 for 2 hours with occasional agitation. Fresh drug-containing medium was then 585 added for an incubation of 24 hours before fixation and permeabilisation. SV40 T-antigens 
592
Vero cells were chilled at 4 o C for 1 hour before addition of SV40 virions at an MOI of 3 in 593 chilled growth medium. Cells were maintained at 4 o C for 1 hour with occasional agitation to 594 facilitate binding. Pre-warmed growth medium containing drug was then added before 595 incubation at 37 o C for 10 hours before fixation. Following permeabilisation, immunostaining 596 was performed to detect SV40 VP2/3 and the ER using calnexin. DAPI was used to visualise 597 nucleic acids. 
601
Following internalisation, MCPyV and SV40 require an acidic environment. In addition to 602 lowered pH, MCPyV also requires the activity of K + and T-type Ca 2+ channels whilst 603 trafficking to the ER (A). Fusion to the ER of both MCPyV and SV40 is dependent upon 604 NAADP-sensitive Ca 2+ channel activity where the capsid disassembles, exposing the minor 605 capsid proteins VP2/3 prior to translocation into the cytoplasm, which is inhibited by 606 verapamil and tetrandrine.
